Marinomed Biotech AG, ATMARINOMED6

Marinomed Biotech AG, ATMARINOMED6

23.05.2023 - 07:48:22

EQS-News: Marinomed Biotech AG reports best first quarter in company history

All amounts in ? thousand Q1 2023 Q1 2022 Revenues 3,319.0 2,411.6 Operating result (EBIT) -1,391.0 -1,240.9 Result for the period -2,059.8 -1,837.6 R&D expenses -1,938.8 -1,571.6 Cash flow utilized by operating activities -755,8 -979,5 ? ???? 31.03.2023 ?????? 31.12.2022 Cash and cash equivalents 7,022.4 8,175.4 Current financial liabilities 1,814.0 2,445.6 Non-current financial liabilities 20,081.8 20,182.1 Capital and reserves -5,567.0 -4,157.1 Balance sheet total 19,475.1 22,286.6

Details of the Q1/ 2023 conference call:

Marinomed Biotech AG will inform on the first quarter results in a conference call held in English today at 10 a.m. (CEST). Andreas Grassauer, CEO, and Pascal Schmidt, CFO will lead through the call.

To register, please follow this link:

Participants will then receive an email with further information on how to join the conference call. The web presentation ( will start at the same time as the conference call. Only registered participants will be able to follow the online presentation.

The presentation for the conference call and the annual report will be available on the Company's website at the following link:?

About Marinomed Biotech AG:

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv? and the virus-blocking activity of iota-carrageenan. The Marinosolv? technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose?-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit:

?For further inquiries contact:

Marinomed Biotech AG PR: Lucia Mayr-Harting T: +43 2262 90300 158 email:?pr@marinomed.comIR: Stephanie Kniep T: +43 2262 90300 226 email:? International Media ContactMetrum Communications: Roland Mayrl T: +43?664 6126228 email:? ?


This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as ?anticipate,? ?believe?, ?estimate?, ?expect?, ?intend?, ?plan?, ?project? and ?target?. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv? and Carragelose? are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

23.05.2023 CET/CEST This Corporate News was distributed by EQS Group AG.

Language: English Company: Marinomed Biotech AG Hovengasse 25 2100 Korneuburg

Austria Phone: +43 2262 90300 E-mail: Internet: ISIN: ATMARINOMED6 WKN: A2N9MM Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) EQS News ID: 1638423 ? End of News EQS News Service